Future TRAIL-therapeutic strategies must be aimed at restoring TRAIL sensitivity by increasing functional TRAIL-receptors, blocking decoy receptors and other TRAIL-binding proteins as well as by counter-acting the inflammatory micro-milieu in pancreatic cancer. Here, TNFSF10 is linked to pancreatic neoplasm.